Solentim awarded two Queen’s Awards for Enterprise
Solentim, based in Bournemouth, Dorset, is delighted to have been given awards for both International Trade and Innovation.
PRESS RELEASE – 21st April, 2018, BOURNEMOUTH: Dorset-based Solentim awarded two Queen’s Awards for Enterprise
The Queen’s Awards for Enterprise are the UK’s most prestigious business awards, given only to companies or individuals who are outstanding in their field. Awards are presented to companies for International Trade, Innovation, Sustainable Development and Enterprise Promotion.
Solentim, based in Bournemouth, Dorset, is delighted to have been given awards for both International Trade and Innovation. Announced on 21st April 2018, only a small handful of British businesses have been presented with the accolades.
Solentim is a life science business built upon the success of an imaging tool for use in the development of cell lines for the pharmaceutical industry. High-throughput techniques have been applied to the biological sciences to accelerate the discovery process. These techniques require the identification of single cells to ensure that the active agent produced is consistent throughout each batch. The Cell Metric® is the imaging system that the company has developed as a solution for this task. The patent protected technology scans an industry standard culture plate and can identify a single cell. It operates at high-resolution, high-contrast, and at high-speeds. The Cell Metric delivers an efficient imaging solution to customers, and typically halves the time taken to develop cell lines. Development of the system, and its associated benefits, has been recognised with the Queen’s Award for Innovation.
Innovation award winners have demonstrated that their business has dramatically improved in areas of performance and commercial success by either outstanding innovation, continued over at least two years, or continuous innovation and development over at least five years. Innovation achievements are assessed for: invention, design or production; performance of services and products; marketing and distribution; or after-sales support of goods or services.
International Trade award winners have demonstrated that their business has achieved substantial growth in overseas earnings and in commercial success (for their business size and sector) through either outstanding achievement over three years or continuous achievement over six years.
Solentim co-Founder and Director Aaron Figg commented “I am absolutely delighted that Solentim has been awarded these prestigious awards. This is a great testament to the highly skilled and committed team that we’ve put together over the last seven years and I’d like to thank them for their hard work and dedication”.
Solentim is based in the UK when it benefits from the precision engineering and manufacturing expertise to supply many of the bespoke components needed to make Cell Metric, but over 90% of sales are overseas.
Solentim has achieved outstanding continuous growth from international trade in the last three years in accordance with the award entry criteria. The composition of the cell line development market makes exporting essential to Solentim.
The US plays host to the biggest cell line development market in the world and the company has a wholly-owned US subsidiary to cater to US customers. In other parts of the world, Solentim either sells to customers directly, or through its network of distributors, with many customers in China, Japan, South Korea, Germany, Switzerland and Australia.
Mr Figg added: “I’m very proud of the contribution that Solentim makes to the global drug discovery market. Our products are helping to make the development of essential drugs and therapies faster and cheaper and will ultimately help more patients to live for longer and have a better quality of life. That to me is the ultimate company goal and it’s what has driven our team to innovate and achieve international success”.
Solentim employs over 40 people, with the majority based in the UK at its headquarters in Bournemouth, Dorset.
The major societal benefit derived from Solentim’s innovation is the ability to bring new therapeutic drugs to market, more quickly and with better results for the same resource expenditure. As a result, Solentim is having a direct positive impact on the pharmaceutical industry’s ability to develop drugs that cure or bring therapeutic relief to millions of sufferers of diseases including: Cancer, Cardiovascular Disease, Arthritis, Psoriasis, and Multiple Sclerosis.